Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

GenCure announces breakthrough first run of 80-liter bioreactor

August 14, 2019 By Cade Hildreth, Founder & President Leave a Comment

Biomanufacturing CDMO among first to harvest adult stem cells at large scale

SAN ANTONIO, Texas – In a breakthrough for the regenerative medicine industry, GenCure announced today that its biomanufacturing services team has successfully completed production runs expanding and harvesting human mesenchymal stem cells (hMSCs) in an 80-liter bioreactor. GenCure, a subsidiary of BioBridge Global (BBG), announced a major expansion of its biomanufacturing facilities in February of this year. [Read more…]

Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley

August 6, 2019 By Cade Hildreth, Founder & President Leave a Comment

Founded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.

In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory. [Read more…]

Mesoblast’s Mesenchymal Precursor Cell (MPC) Therapy Receives Orphan Drug Designation

June 24, 2019 By Cade Hildreth, Founder & President Leave a Comment

Mesoblast (ASX:MSB; Nasdaq: MESO) announced that the U.S. FDA granted the company’s product candidate, Revascor, Orphan Drug Designation for prevention of gastrointestinal bleeding in patients with left ventricular assist devices.

Revascor, Mesenchymal Precursor Cells

Revascor is Mesoblast’s investigational cell therapy composed of 150 million allogeneic mesenchymal precursor cells (MPCs). [Read more…]

Pluristem Therapeutics, Interview with Yaky Yanay, President and Co-CEO

March 28, 2019 By Cade Hildreth, Founder & President 1 Comment

Pluristem Therapeutics (PSTI) is a clinical-stage company that is a proprietary 3D manufacturing technology to develop placental cell therapies for conditions that include ischemia, muscle injury, and exposure to radiation. I had the honor of interviewing Mr. Yaky Yanay, President and Co-CEO of Pluristem Therapeutics.

In this interview, we discuss the history of Pluristem Therapeutics, its clinical-stage products, intellectual property (IP) portfolio, marketing strategy and future directions.

Enjoy these insights into Pluristem Therapeutics, a world-class leader in cell therapy manufacturing and placental-derived products. [Read more…]

Cynata Completes Phase I Trial for CYP-001, Triggers Option Window for Fujifilm

December 19, 2018 By Cade Hildreth, Founder & President Leave a Comment

It is official. Australian stem cell company Cynata Therapeutics has completed the world’s first Phase I trial involving an induced pluripotent stem cell (iPSC) derived therapeutic product. The landmark study involved the company’s lead product, CYP-001, an iPSC-derived mesenchymal stem cell (MSC) product that can be manufactured at therapeutic grade and at mass scale using Cynata’s Cymerus™ platform technology.

Next, the company will be initiating Phase II trials in graft-versus-host disease (GvHD), critical limb ischemia (CLI) and osteoarthritis, showcasing the power of Cynata’s platform technology to be leveraged across multiple indications. Osteoarthritis will be Cynata’s largest clinical trial to date and also one of the largest ever for an MSC product. [Read more…]